PCI Biotech update
PCI Biotech update
Oslo (Norway), 23 October 2025 - PCI Biotech (OSE: PCIB) today provides an
update on the ongoing evaluation of its operations.
Reference is made to the company's announcements dated 18(th) August 2025 and
25(th) September 2025, as well as the interim report for the first half of 2025
published on 29(th) August 2025. As previously communicated, current activities
are focused on the evaluation of a new bioprocessing technology by an
undisclosed party, conducted under a material transfer agreement without
financial terms.
The company's limited operations and the group's future rely on continued
interest under the ongoing technology evaluation. At present, there are no
active discussions regarding strategic alternatives. The liquidity position of
the PCI Biotech group is critical, and there can be no assurance that PCI
Biotech will be able to secure financing. These material uncertainties cast
significant doubt on the PCI Biotech group's ability to continue as a going
concern.
The management team has been restructured and now consists solely of the CEO
position in the parent company, PCI Biotech Holding ASA. The wholly owned
subsidiary, PCI Biotech AS, has opted not to have a CEO position. The board of
directors of PCI Biotech Holding ASA will assume a similar role in the wholly
owned subsidiary PCI Biotech AS.
Further information and updates will be provided when applicable.
For further information, please contact:
Ronny Skuggedal, CEO
Email: [email protected]
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on developing and
commercialising new technologies and novel therapies through its photochemical
technology platform originating from world-leading research at the Oslo
University Hospital. The technology platform was until August 2025 under
development in two different areas. (1) Photochemical lysis (PCL), inducing
selective light-triggered cell lysis, which may enhance yield and purity in
viral vector manufacturing. (2) Photochemical internalisation (PCI), inducing
light-triggered endosomal release, which may unlock the potential of a wide
array of modalities.
For further information, please visit: www.pcibiotech.com
Contact information:?PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.